Delving into the Latest Updates on Sacituzumab tirumotecan with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264

+ [7]

Target

Top I x Trop-2

Action

inhibitors

Mechanism

TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases+ [6]

Active Indication

Hormone receptor positive HER2 negative breast cancerEGFR-mutated non-small Cell Lung CancerEGFR positive Non-squamous non-small cell lung cancer+ [73]

Inactive Indication-

Originator Organization

Sichuan Kelun Pharmaceutical Co., Ltd.

Active Organization

Merck Sharp & Dohme LLC

MSD R&D (China) Co. Ltd.

KLUS Pharma, Inc.

+ [4]

Inactive Organization-

License Organization

Sichuan Kelun Botai Biomedicine Co., Ltd.

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

China (22 Nov 2024),

Triple Negative Breast Cancer

RegulationBreakthrough Therapy (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Sequence Code 27958L

Source: *****

Sequence Code 319372635H

Source: *****

Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advanced or metastatic urothelial cancer (UC), representing a promising therapeutic target. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes payload delivery to tumor cells. We present preliminary results for sac-TMT monotherapy from cohort 9 of the phase 1/2 2870-001/KL264-01 study in participants with advanced or metastatic UC.

PARTICIPANTS AND METHODS:

Eligible participants with locally advanced or metastatic UC and disease progression on one or more prior line of platinum-based chemotherapy and anti-programmed cell death protein 1/programmed cell death-ligand 1 therapy received sac-TMT 5 mg/kg intravenously every 2 weeks until disease progression, unacceptable toxicity, or participant/physician decision. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST version 1.1. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.

RESULTS:

By data cut-off (17 February 2025), 49 participants were treated with sac-TMT; 37 (76%) had received two or more prior lines of therapy. Median follow-up for this analysis was 18.8 months. The confirmed ORR was 31% [95% confidence interval (CI), 18% to 45%] and the disease control rate was 71% (95% CI 57% to 83%). Median DOR was not reached [range 2.1-22.2+ (+ indicates censored data for the longest DOR, suggesting that patients may have achieved longer remission duration) months], and the 12-month probability of sustained response was 53%. Median PFS and OS were 5.5 months (95% CI 3.6-7.2 months) and 12.1 months (95% CI, 9.9-15.3 months), with 18-month rates of 26% and 33%, respectively. Grade 3/4 treatment-related adverse events (AEs) occurred in 31 participants (63%), and the most common (≥5%) were anemia (41%), decreased neutrophil count (35%), decreased white blood cell count (20%), stomatitis (12%), and decreased platelet count (8%). There were no grade 5 treatment-related AEs or febrile neutropenia events.

CONCLUSIONS:

Sac-TMT 5 mg/kg monotherapy every 2 weeks demonstrated promising antitumor activity in participants with heavily pretreated advanced or metastatic UC, with a manageable safety profile, warranting further evaluation of sac-TMT in this population.

15 Feb 2026·CANCER

Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC

Author: Lawrence, Leah

15 Feb 2026·CANCER

TROP2‐targeted ADCs demonstrate survival benefit for patients with advanced triple‐negative breast cancer

Author: Lawrence, Leah

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, TROP2‐targeted antibody–drug conjugates demonstrate a survival benefit for patients with advanced triple‐negative breast cancer. In addition, sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR ‐mutant advanced non–small cell lung cancer, and an immunochemotherapy regimen demonstrates survival benefits for patients with platinum‐resistant ovarian cancer.

115

News (Medical) associated with Sacituzumab tirumotecan

16 hours ago

·www.prnewswire.com

Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer

Late-Phase Research Presented at Society of Gynecologic Oncology Annual Meeting FORT MYERS, Fla., April 13, 2026 /PRNewswire/ -- Late-phase clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) has led to the U.S. Food & Drug Administration's (FDA) recent approval of KEYTRUDA and KEYTRUDA QLEX as the first and only immunotherapy options of their kind for adults with certain hard-to-treat ovarian-related cancers. These breakthrough treatments slow the progression of certain ovarian cancers, improving outcomes and extending lives for patients with cancers that have a specific marker called PD-L1 (present in approximately 75% of cases) and no longer respond to standard platinum-based chemotherapy. Continue Reading Bradley Monk, MD, FCS medical director of late-phase clinical research, presented the final analysis results at the Society of Gynecologic Oncology (SGO) annual meeting in San Juan, Puerto Rico. Bradley Monk, MD, FCS medical director of late-phase clinical research, presented the final analysis results at the Society of Gynecologic Oncology (SGO) annual meeting in San Juan, Puerto Rico concurrent with their publication in The Lancet. "I am honored to be part of such an exceptional group in helping bring new therapies to the ovarian cancer landscape, both through our research demonstrating statistically significant and clinically meaningful improvements in overall survival," said Dr. Monk. In the U.S., about 21,000 women are expected to be diagnosed with ovarian cancer in 2026, most over age 55. Platinum‑resistant ovarian cancer occurs when the disease returns or progresses within six months of platinum‑based chemotherapy, making it harder to treat. As Dr. Monk explains, "For patients with platinum-resistant ovarian cancer, these new FDA-approved pembrolizumab-based treatments can provide additional options and potentially more time." Dr. Monk's SGO annual meeting presentation is titled: "Pembrolizumab vs Placebo Plus weekly Paclitaxel A+ over 1 sign Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Final Analysis Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study." He will also present a poster, "GOG-3119/ENGOT-en29/TroFuse-033: A Phase 3, Randomized Study of Sacituzumab Tirumotecan Plus Pembrolizumab vs. Pembrolizumab Alone as First-Line Maintenance Therapy for Mismatch Repair-Proficient Endometrial Cancer." Dr. Monk, a board-certified gynecologic oncologist and principal investigator focused primarily on the prevention and treatment of gynecologic cancers, is a recognized leader in practice-changing clinical research. In partnership with Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, FCS provides patients with access to more clinical trial opportunities than any single cancer center in Florida. At any point in time, more than 180 active early and late-phase clinical trials are underway at FCS. About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com) For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program. FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. Through its robust clinical research program with Sarah Cannon Research Institute (SCRI) and a suite of independent site management programs, with advanced clinical trial matching technology, FCS offers patients innovative therapies close to home. Each year, FCS conducts more than 180 active clinical trials that directly elevate patient care and accelerate progress in oncology. Many of the cancer drugs approved by the FDA in the U.S over the past decade were accessible to patients at FCS through clinical trial participation before receiving approval. Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes. SOURCE Florida Cancer Specialists & Research Institute 21% more press release views with Request a Demo

Phase 3ASCOImmunotherapy

09 Apr 2026

·www.prnewswire.com

Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development

CHENGDU, China, April 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the Stock Exchange has approved the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules to the Company. As the Company has satisfied the relevant requirements under the Listing Rules, it has been approved by the Stock Exchange to remove the "B" marker from its stock code, effective from April 14, 2026. The removal of the "B" marker signifies that Kelun-Biotech has met higher standards in key operating metrics, representing a new stage of development for the Company. The essence of this "new stage of development" is reflected across three major dimensions: accelerated R&D and product launch, achievement of global collaboration milestones, and iteration of innovative assets. Accelerated product approvals and significant time-to-market efficiency: Within three years since its listing, Kelun-Biotech has already secured approvals for 4 products across 8 indications, among which 3 products with 5 indications have been included in China's National Reimbursement Drug List (NRDL), accomplishing a fully integrated platform spanning from R&D to commercialization. Leveraging this end-to-end drug development platform, the Company will further advance its pipeline to address unmet medical needs in oncology and other major disease areas. Steady progress in global partnerships with anticipated milestones: The Company continues to expand its global footprint through collaborations with world leading partners, including MSD and Crescent Biopharma, steadily advancing the global development of relevant assets. Notably, MSD has evaluated 17 global Phase III clinical trials for sacituzumab tirumotecan (sac-TMT, 佳泰莱®), and multiple studies are approaching the data readout stage and further achieving more important milestones. Successive innovation from best-in-class (BIC) to first-in-class (FIC): Leveraging its leading technology platforms in ADC and novel conjugation drugs, biologics, and small molecules, the Company has built a differentiated innovative pipeline. So far, sac-TMT has demonstrated strong competitiveness worldwide as a representative BIC potential asset. Moreover, the Company is advancing a portfolio of potential FIC candidates integrating new targets, new mechanisms, and new technologies, continuously expanding the boundaries of original innovation and further strengthening its long-term sustainable development. Dr. Michael Ge, CEO of Kelun-Biotech, said: "We are pleased that our company has met the relevant requirements under the HKEX Listing Rules and has successfully removed the 'B' marker from its stock code. This milestone reflects our strong capabilities in biopharmaceutical innovation and value realization. Supported by a solid financial position, we will continue to enrich our innovative and synergistic pipeline, accelerate product development, benefit a broader patient population and create long-term value for shareholders." About Kelun-Biotech Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit . SOURCE Kelun-Biotech 21% more press release views with Request a Demo

Phase 3Clinical ResultNDA

03 Apr 2026

·www.prnewswire.com

Next Generation Drug Conjugates (NDCs) Market worth $42.55 billion by 2035 | MarketsandMarkets™

DELRAY BEACH, Fla., April 3, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 market data Tables and 60 Figures spread through 270 Pages and in-depth TOC on "Next Generation Drug Conjugates Market - Global Forecast to 2035" Next Generation Drug Conjugates Market Size & Forecast: Market Size Available for Years: 2026–2035 2026 Market Size: USD 15.75 billion 2035 Projected Market Size: USD 42.55 billion CAGR (2026–2035): 11.7% Next Generation Drug Conjugates Market Trends & Insights: By type, the peptide-radionuclide conjugate is projected to witness the highest CAGR of 14.6% between 2026 and 2035. By indication, breast cancer is expected to dominate the global next generation drug conjugates market in 2025 with a share of 45.9%. North America is projected to be the fastest-growing regional segment at a CAGR of 13.2% during the forecast period. Download PDF Brochure @ The growing prevalence of hematologic malignancies and solid tumors is a major driver for the next generation drug conjugates market. Additionally, continuous advancements in conjugation technologies, including improvements in targeting ligands, linker chemistry, payload design, and manufacturing processes, are enhancing the efficacy, safety, and scalability of these therapies. By product, The Enhertu segment accounted for the largest share of the global next generation drug conjugates market in 2025. the next generation drug conjugates market is segmented into Enhertu, Amvuttra, Pluvicto, Trodelvy, Sacituzumab Tirumotecan (SAC-TMT), Zilebesiran, 225Ac-PSMA-617, other commercialized products, and other pipeline products. The Enhertu dominated the market share in 2025, driven by its superior clinical efficacy, strong global adoption, and expanding approvals across multiple HER2-targeted indications, particularly in breast cancer. Its growing use in HER2-low populations and ongoing clinical trials in lung and gastric cancers further support its market leadership. Additionally, the increasing prevalence of breast cancer and the rising demand for targeted therapies continue to boost the uptake of Enhertu, reinforcing its dominant position in the global NGDC market. Request Sample Pages@ By Targeting ligand, Amino sugar is estimated to be the fastest-growing target ligand segment. The global next generation drug conjugates market is segmented by target ligand into antibodies, amino sugars, peptides, and other targeting ligands. In 2025, the amino sugar segment is projected to be the fastest growing during the forecast period, driven by its emerging role in targeted delivery and improved cellular uptake. Amino sugar-based ligands offer enhanced biocompatibility and potential for selective binding, supporting their increasing adoption in novel drug conjugate development and expanding research applications in precision oncology. North America accounted for the largest regional share in the global next generation drug conjugates market in 2025. North America accounted for the largest share of regional revenues in the next generation drug conjugates (NGDC) market and remains the primary growth engine. The region's dominance is driven by a high concentration of leading biopharmaceutical companies, advanced research institutions, and specialized cancer centers, along with strong regulatory support from the FDA and rapid adoption of innovative targeted therapies such as antibody-drug conjugates. Robust oncology pipelines, significant NIH and private funding, and an active clinical trials landscape position the US as the key innovation hub for NGDCs, while Canada contributes steadily through expanding healthcare infrastructure, increasing cancer research initiatives, and growing adoption of advanced oncology treatments. Inquire Before Buying@ Top Companies in Next Generation Drug Conjugates Market: The Top Companies in Next Generation Drug Conjugates Market include Alnylam Pharmaceuticals, Inc (US), Gilead Sciences, Inc (Immunomedics) (US), Novartis AG (Switzerland), AstraZeneca (UK), Daiichi Sankyo, Company Limited (Japan), Ionis Pharmaceuticals, Inc. (US), Rakuten Group, Inc. (US), Novo Nordisk (Dicerna Pharmaceuticals) (Denmark), ADC Therapeutics SA (Switzerland), Sanofi (France), Arrowhead Pharmaceuticals (US), and AbbVie, Inc (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Related Reports: Antibody Discovery Market - Global Forecast to 2030 Antibody Therapeutics Market - Global Forecast to 2028 Oligonucleotide Synthesis Market - Global Forecast to 2030 Peptide Synthesis Market - Global Forecast to 2029 Drug Discovery Services Market - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency. To find out more, visit ™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: Logo - SOURCE MarketsandMarkets 21% more press release views with Request a Demo

100 Deals associated with Sacituzumab tirumotecan

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hormone receptor positive HER2 negative breast cancer	China	Sichuan Kelun Botai Biomedicine Co., Ltd.	02 Feb 2026
EGFR-mutated non-small Cell Lung Cancer	China	Sichuan Kelun Botai Biomedicine Co., Ltd.	30 Sep 2025
EGFR positive Non-squamous non-small cell lung cancer	China	Sichuan Kelun Botai Biomedicine Co., Ltd.	04 Mar 2025
Triple Negative Breast Cancer	China	Sichuan Kelun Botai Biomedicine Co., Ltd.	22 Nov 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Urothelial Carcinoma	Phase 3	United States	Merck Sharp & Dohme LLC	15 Apr 2026
Locally Advanced Urothelial Carcinoma	Phase 3	Israel	Merck Sharp & Dohme LLC	15 Apr 2026
Bladder Cancer	Phase 3	United States	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	China	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	Japan	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	Argentina	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	Australia	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	Belgium	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	Brazil	MSD R&D (China) Co. Ltd.	03 Apr 2026
Bladder Cancer	Phase 3	Canada	MSD R&D (China) Co. Ltd.	03 Apr 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05631262 (OptiTROP-Lung03, ESMO_ELCC2026 \| PRNewswire) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	137	Sacituzumab Tirumotecan	jxsimotitn(tcyjguqwgy) = qpsjgrbouk brinfxkbzy (vamdrxkjhr ) View more	Positive	27 Mar 2026
				Docetaxel	jxsimotitn(tcyjguqwgy) = hffpctmgoc brinfxkbzy (vamdrxkjhr ) View more
NCT06952504 (GOG-3119, ESGO2026)	Phase 3	Endometrial Carcinoma First line \| Maintenance pMMR	529	Sacituzumab tirumotecan + Pembrolizumab	czuqavzgmz(adksxbmeul) = sfcunsemru juswpdedxm (wwiwhhzkwi ) View more	Positive	28 Feb 2026
				Pembrolizumab	eeuklaobzj(rklcsyyskw) = nierbhknuf gzydwstymn (kkqyvxcvmy ) View more
NCT06448312 (OptiTROP-Lung05, PRNewswire) Manual	Phase 3	PD-L1 positive Non-Small Cell Lung Cancer First line PD-L1 Positive	-	sacituzumab tirumotecan + pembrolizumab	omsfqzfcxx(hkyaddqqtn) = Sac-TMT, in combination with pembrolizumab, as a first-line treatment for PD-L1-positive NSCLC, has demonstrated a statistically significant and clinically meaningful improvement in PFS, the study's primary endpoint. pqbzlarjum (ekyhwelnbo ) Met View more	Positive	24 Nov 2025
				pembrolizumab
NCT04152499 (MK-2870-001 \| KL264-01, Ann Oncol \| Pubmed \| PRNewswire) Manual	Phase 1/2	Advanced Urothelial Carcinoma	49	Sacituzumab Tirumotecan 5 mg/kg	tvcjnucins(dsstdmunwn) = iprdqgyktr nuanctrdds (bdqihggvpt, 18 - 45) View more	Positive	20 Nov 2025
NCT05351788 (OptiTROP-Lung01, Pubmed \| Nat Med)	Phase 2	Advanced Lung Non-Small Cell Carcinoma First line	103	Tagitanlimab 1,200 mg every 3 weeksvery 3 weeks + Tagitanlimab 1,200 mg every 3 weeks	gwzbeycwhl(wnmatjveaa) = hiuyrwjfvu gleuuvbbkm (dqupdgsjjm ) View more	Positive	01 Nov 2025
				Sacituzumab tirumotecan 5 mg kg-1 every 2 weeks + Tagitanlimab 900 mg every 2 weeks	gwzbeycwhl(wnmatjveaa) = vcmjsswhie gleuuvbbkm (dqupdgsjjm ) View more
NCT05870319 (OptiTROP-Lung04, Pubmed \| N Engl J Med) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	376	Sacituzumab tirumotecan (sac-TMT)	wtshcleiqd(necytrmvow) = jynspwbqyb xifhzwlixz (fcxpkhqkrr ) View more	Positive	19 Oct 2025
				Pemetrexed + platinum-based chemotherapy	wtshcleiqd(necytrmvow) = zfdxocgimv xifhzwlixz (fcxpkhqkrr ) View more
NCT06081959 (OptiTROP-Breast02, ESMO2025) Manual	Phase 3	Hormone receptor positive HER2 negative breast cancer Second line HR Positive \| HER2 Negative	399	Sacituzumab tirumotecan (sac-TMT) 5 mg/kg Q2W	daasqzwejd(qitmebdicn) = sbgkmybojl iioqlhhsxl (lxfmdxqmwz ) View more	Positive	17 Oct 2025
				Investigator's choice of chemotherapy (ICC)	daasqzwejd(qitmebdicn) = fsmwetmnbs iioqlhhsxl (lxfmdxqmwz ) View more
NCT04152499 (ESMO2025)	Phase 1/2	Advanced Cervical Carcinoma TROP2 expression	58	Sacituzumab tirumotecan (Sac-TMT) 4 mg/kg	ugbmjtydyb(zgvsjlcoah) = aovhtrwdpb zhabvkevjy (uouhddlgol, 17 - 41) View more	Positive	17 Oct 2025
NCT05816252 (MK-2870-003, ESMO2025)	Phase 2	PD-L1 positive Lung Cancer First line PD-L1-positive	50	Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro)	zzqbejgkmy(auichhmgbu) = jgwyfazrie dcvttwrjqo (mkeciwovah ) View more	Positive	17 Oct 2025
				Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) (PD-L1 TPS ≥50%)	zzqbejgkmy(auichhmgbu) = vlzgkmwnag dcvttwrjqo (mkeciwovah ) View more
NCT05642780 (MK-2870-002, ESMO2025)	Phase 2	Metastatic castration-resistant prostate cancer	46	Sacituzumab Tirumotecan (sac-TMT) 4 mg/kg + Pembrolizumab (Pembro)	deqaxgnelo(ketrczlnpb) = fmhzvkromp izotxcaymm (owmwioxbxr, 12.2–73.8) View more	Positive	17 Oct 2025
				Sacituzumab Tirumotecan (sac-TMT) 5 mg/kg + Pembrolizumab (Pembro)	deqaxgnelo(ketrczlnpb) = dseyrsirim izotxcaymm (owmwioxbxr, 20.8–53.8) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.